Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, explains the small potential risk of breast cancer associated with hormonal birth control.
Hormonal birth control carries risks of adverse events, as do all medications, and one association appears to be a very slightly increased risk of breast cancer, according to Debra Patt, MD, PhD, MBA, executive vice president, Texas Oncology.
Transcript
Should people be concerned over the recent study gaining media attention that hormonal birth control increases risk of breast cancer?
Sure, I think that with any drug that you take, you should always be cognizant of the desired effects and unintended side effects of any medication. For patients, hormonal contraception can very slightly, and I will say very slightly, increase the risk for breast cancer. We know that's a cumulative risk.
I think for every patient, like with any therapy, you need to carefully think about the effects that are desired in contrast to the potential side effects, because it's not a universal recommendation for every patient.
For example, if you have a patient that is just desiring a mechanism of contraception, and they have a very high breast cancer risk because of a genetic susceptibility or family members who've had breast cancer, for them, the decision might be very different than someone who has no family history of breast cancer and has contraindications to other forms of contraception. So, I think it varies per patient. But yes, it's a risk. But it's a very small risk.
Actually, I think that most patients take oral contraceptives safely without any increased risk for breast cancer. The truth is—and everyone asks, because breast cancer is common—if this caused it or that caused it, but breast cancer is just common; 1 out of 8 women will get breast cancer in their lifetime. So, the percentage of that risk that you can attribute to a history of oral contraceptive use is really quite small.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More